SFA-ENVIRO
24.5.2022 15:02:06 CEST | Business Wire | Press release
SFA, a World-Renowned Group, launches its Environmental Division: SFA enviro. Specialized in the design and manufacture of Wastewater Treatment Equipment since 1958, the group is mainly known for having revolutionized the sanitary equipment market.
New division, SFA enviro, the result of the SFA Group's International Growth Strategy.
With more than 1,000 employees in 27 countries worldwide, the SFA Group has a portfolio of leading brands, including Europelec and Aquaturbo. The Group’s core business is closely linked to the Treatment of Municipal and Industrial Wastewater with a DNA focused on the Design and Manufacturing of Aeration Equipment.
Thanks to 100 years of cumulative and international experience, SFA enviro supplies most of the equipment for Wastewater Treatment plants - from pre-treatment to sludge management - including process and treatment tanks and specific ancillary equipment used to settle, decant, aerate, and thicken Wastewater.
Inventiveness is a priority for the SFA Group : Since the beginning, the Group has never stopped looking to the future and adapting to the ever-changing Market Place. Innovation, R&D, respect for the environment and customer service are at the heart of the Group's Core values. The SFA Group is committed to offering high performance with quality products, manufactured in Europe and the USA.
Companies part of SFA enviro Division : Europelec (France), Aquasystems International N.V. (Belgium) and Aquaturbo Systems Inc (USA).
R&D Department works in partnership with French and other higher education and research institutions.
Much of the Equipment has been in service Worldwide for more than 30 to 35 years, with references in many Industrial Sectors such as Dairy Industry, Pulp and Paper, Mining, Food Processing, Meat Rendering, Brewery Industries, Oil and Gas, Pharmaceutical Industry, Sugar production, Livestock and Fish farming etc...
Prestigious Customers : AQUAFIN, METITO, VEOLIA, SEVERN TRENT, SAUR, WATERLEAU, SUEZ, VINCI, NIJHUIS, BENTLEY, PANTAREIN, MAREL, NESTLÉ, ASIATEX, APP SINAR MAS, TOTAL ENERGIES, LACTALIS, SACROFINA, TEREOS, GRUMA, AGROSUPER, UNITED UTILITIES, THAMES WATER SEVERN TRENT,YORKSHIRE WATER, VALERO, SMURFITT KAPPA etc...
The know-how of our skilled workers, some of whom have more than 30 years of experience, is perpetuated through recruitment programs and training of apprentices in the FABRICATION, MACHINING, WELDING, FITTING AND INSTALLLING PLUS COMMISSIONING.
Our brands: Aerospeed®, Aerostream®, Aircomb®, Aquafenr, Aquadecant®, Aquaeromix®, Aquadisc®, Aquafloat®, Aquatube®, Aquaturbo®, Euromix®, Europelec®, Noemi®, Screwpeller®, Sofie® and TLF®.
Learn more: www.sfa-enviro.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220513005310/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
